<DOC>
	<DOCNO>NCT01495104</DOCNO>
	<brief_summary>This open-label , fixed-sequence , two-period study assess effect multiple dose valproate pharmacokinetics RO4917838 steady state vice versa healthy male volunteer . In Period 1 , subject receive valproate 5 day . After washout period 5 day 2 week , subject receive , Period 2 , RO4917838 15 day concomitant valproate Days 11-15 . Anticipated time study 12 week .</brief_summary>
	<brief_title>A Study Effects Valproate Pharmacokinetics RO4917838 Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>Healthy male volunteer , 18 65 year age inclusive Body mass index ( BMI ) 18 30 kg/m2 inclusive Healthy determine investigator basis medical/surgical history , physical examination , clinical laboratory test result , vital sign , 12lead electrocardiogram ( ECG ) Non smoker smoker few 10 cigarette per day History alcoholism , drug abuse addiction within last year prior Day 1 study Alcohol consumption average 24 g alcohol per day History significant cardiovascular , hepatic , renal , respiratory , gastrointestinal , endocrine , immunologic , allergic , dermatologic , hematologic , neurologic , psychiatric disease , cancer Any major illness within 4 week prior dose acute disease state ( e.g . nausea , vomit , fever , diarrhea ) within 7 day study Day 1 Any confirm allergic reaction drug , multiple allergy judgment investigator Positive hepatitis B , hepatitis C HIV infection Involvement investigational study type within 90 day first study drug administration within 5 time elimination halflife test drug , whichever long</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>